Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Apr 24:rs.3.rs-3342413.
doi: 10.21203/rs.3.rs-3342413/v2.

Protein restriction slows the development and progression of Alzheimer's disease in mice

Affiliations

Protein restriction slows the development and progression of Alzheimer's disease in mice

Reji Babygirija et al. Res Sq. .

Update in

Abstract

Dietary protein is a critical regulator of metabolic health and aging. Low protein diets are associated with healthy aging in humans, and many independent groups of researchers have shown that dietary protein restriction (PR) extends the lifespan and healthspan of mice. Here, we examined the effect of PR on metabolic health and the development and progression of Alzheimer's disease (AD) in the 3xTg mouse model of AD. We found that PR has metabolic benefits for 3xTg mice and non-transgenic controls of both sexes, promoting leanness and glycemic control in 3xTg mice and rescuing the glucose intolerance of 3xTg females. We found that PR induces sex-specific alterations in circulating metabolites and in the brain metabolome and lipidome, downregulating sphingolipid subclasses including ceramides, glucosylceramides, and sphingomyelins in 3xTg females. Consumption of a PR diet starting at 6 months of age reduced AD pathology in conjunction with reduced mTORC1 activity, increased autophagy, and had cognitive benefits for 3xTg mice. Finally, PR improved the survival of 3xTg mice. Our results demonstrate that PR slows the progression of AD at molecular and pathological levels, preserves cognition in this mouse model of AD, and suggests that PR or pharmaceutical interventions that mimic the effects of this diet may hold promise as a treatment for AD.

Keywords: 3xTg; Alzheimer’s disease; autophagy; mTORC1; protein restriction.

PubMed Disclaimer

Conflict of interest statement

DWL has received funding from, and is a scientific advisory board member of, Aeovian Pharmaceuticals, which seeks to develop novel, selective mTOR inhibitors for the treatment of various diseases. J.M.D. is a consultant for Evrys Bio and co-founder of Galilei BioSciences.

Figures

Figure 1:
Figure 1:. Protein restriction prevents weight and fat mass gain in 6-month-old 3xTg mice and NTg controls of both sexes.
(A) Experimental design: Male and female 3xTg and non-transgenic mice (NTg) were placed on either a Control or a PR diet starting at 6 months of age, and phenotyped over the course of the next 9 months. (B-E) The body weight (B) of female mice was followed over the course of the experiment, fat mass (C) and lean mass (D) was determined at the start and end of the experiment, and the adiposity (E) was calculated; n=5–7 biologically independent mice per group. (F-G) Food (F) and protein (G) consumption normalized to body weight of female mice at 9 months of age; n=5 biologically independent mice per group. (H-K) The body weight (H) of male mice was followed over the course of the experiment, fat mass (I) and lean mass (J) was determined at the start and end of the experiment, and the adiposity (K) was calculated; n=4–7 biologically independent mice per group. (L-M) Food (L) and protein (M) consumption normalized to body weight of male mice at 9 months of age; n=5 biologically independent mice per group. (C-G, I-M) statistics for the overall effects of genotype (GT), diet, and the interaction represent the p value from a 2-way ANOVA conducted separately for each time point; *p<0.05, from a Sidak’s post-test examining the effect of parameters identified as significant in the 2-way ANOVA. Data represented as mean ± SEM. Schematic in (A) created with www.biorender.com.
Figure 2:
Figure 2:. Sex-specific effects of PR on aspects of energy balance in 3xTg mice.
(A-F) Metabolic chambers were used to determine fuel source utilization, energy expenditure, and spontaneous activity over 24 hours in female (A-C) and male (D-F) 3xTg and NTg control mice fed Control or PR diets for 3 months. (A, D) Respiratory exchange ratio (RER) in females (A) and males (D). (B, E) Energy expenditure normalized to body weight in females (B) and males (E). (C, F) Spontaneous activity of females (C) and males (F). (A-F) n = 4–5 biologically independent mice per group, statistics for the overall effects of genotype (GT), diet, and the interaction represent the p value from a 2-way ANOVA conducted separately for the light and dark cycles, *p<0.05, from a Sidak’s post-test examining the effect of parameters identified as significant in the 2-way ANOVA. Data represented as mean ± SEM.
Figure 3:
Figure 3:. A PR diet ameliorates the impaired glycemic control of 3xTg female mice.
(A-C) Glucose (A), insulin (B), and pyruvate (C) tolerance tests were performed in female mice after three months on Control or PR diets; n = 7–11 mice/group. (D) Heat map representation of all the metabolic parameters in 3xTg and NTg female mice; color represents the log2 fold-change vs. NTg mice fed a Control diet. (E-G) Glucose (E), insulin (F), and pyruvate (G) tolerance tests were performed in male mice after three months on Control or PR diets; n=7–10 mice per group. (H) Heat map representation of all the metabolic parameters in 3xTg and NTg male mice; color represents the log2 fold-change vs. NTg mice fed a Control diet. (A-C, E-G) statistics for the overall effects of genotype (GT), diet, and the interaction represent the p value from a 2-way ANOVA, *p<0.05, from a Sidak’s post-test examining the effect of parameters identified as significant in the 2-way ANOVA. Data represented as mean ± SEM.
Figure 4:
Figure 4:. PR induces sex specific shifts in the brain metabolome of 3xTg mice.
Untargeted metabolomics analysis was conducted on the whole brain of 3xTg (A-B) female and (C-D) male mice fed the indicated diets. (A, C) Principal Component Analysis (PCA) of brain metabolites from 3xTg females and males. (B, D) Volcano plots display altered brain metabolites, with blue and red indicating significantly decreased and increased metabolites between control and PR-fed 3xTg groups. Gray dots indicate metabolites that exhibited no significant differences. (Unadjusted P value < 0.05) with a > 2-fold change are labeled on the volcano plot. (E) Significantly up and down regulated pathways for each sex and diet were determined using metabolite set enrichment analysis (MSEA). n = 4–5 biologically independent mice per group, p < 0.05. Shared pathways between females and males are highlighted.
Figure 5:
Figure 5:. PR induces sex-specific shifts in the brain sphingolipids of 3xTg mice.
(A-H) Targeted analysis of sphingolipids in the whole brain of NTg and 3xTg mice fed the indicated diets. (A, E) Heat map of the sphingolipid classes (ceramides, sphingomyelins and glucosylceramides) that are altered by PR feeding in NTg and 3xTg female and male mice. The black box highlights the sphingolipid subclasses downregulated in 3xTg-PR fed females. (B-D, F-H) Statistically significant subclasses of sphingolipids in 3xTg females (B-D) and males (F-H). (B, F) Glucosylceramides, (C, G) Ceramides and (D, H) Sphingomyelins in the brains of 3xTg female and male mice. (A-H) n=4–5 biologically independent mice per group. Statistics for the overall effects of diet, lipid and the interaction represent the p value from a 2-way ANOVA; *p<0.05, from a Sidak’s post-test for the effect of PR on each lipid. Cer: Ceramides; SM: Sphingomyelins; GlcCer: Glucosylceramides.
Figure 6:
Figure 6:. PR improves AD neuropathology in both female and male 3xTg mice.
(A-K) Analysis of AD neuropathology in female (A-E) and male (F-J) 3xTg mice fed the indicated diets from 6–15 months of age. (A, F) Representative images of Thioflavin-S staining of plaques in the hippocampus of female (A) and male (F) 3xTg mice. 4x and 10x magnification shown with and without DAPI; scale bar in the 10x image is 400μM. (B, G) Quantification of plaque density in females (B) and males (G), n=4 biologically independent mice per group. (C, H)Soluble and insoluble fractions of Aβ (1–40) and Aβ (1–42) concentration in the brain of female (C) and male (H) 3xTg mice was determined by ELISA, n=4 biologically independent mice per group. (D, I) Western blot analysis of phosphorylated T231 Tau in female (D) and male (I) 3xTg mice, n=4–5 biologically independent mice per group. (B,G) *p<0.05, t-test. (C, H) statistics for the overall effects of diet, and solubility represent the p value from a 2-way ANOVA, *p<0.05, from a Sidak’s post-test examining the effect of parameters identified as significant in the 2-way ANOVA. (D, I) *p<0.05, one way ANOVA followed by Tukey’s test (E, J) Immunostaining and quantification of 5 μm paraffin-embedded brain slices for astrocytes (GFAP) and microglia (Iba1) in female (E) and male (J) 3xTg mice. Scale bar is 200 μM. (E, J) *p<0.05, t-test (K) Heat map representation of the neuropathological findings in female and male 3xTg mice; log2 fold-change relative to 3xTg Control-fed mice of each sex. Data represented as mean ± SEM.
Figure 7:
Figure 7:. PR reduces mTORC1 signaling and p62 expression in the brain of female 3xTgmice.
(A) The phosphorylation of S6K1 and 4E-BP1, and the expression of p62, was assessed by Western blotting of whole brain lysate. (B, C) Quantification of the phosphorylation of T389 S6K1 (B) and T37/S46 4E-BP1 (C), relative to expression of S6K1 and 4E-BP1, respectively. (D) Quantification of p62 expression relative to expression of HSP90. (E) Heatmap representation of the western blot substrates in both females and males. (B-D) n=3–4 biologically independent mice per group; statistics for the overall effects of genotype (GT), diet, and the interaction represent the p value from a 2-way ANOVA, *p<0.05, from a Sidak’s post-test examining the effect of parameters identified as significant in the 2-way ANOVA. Data represented as mean ± SEM.
Figure 8:
Figure 8:. PR improves cognitive performance of 3xTg female and male mice.
(A-B) The behavior of female mice was examined at 12 months of age after mice were fed the indicated diets for 6 months. (A) The preference for a novel object over a familiar object was assayed in female mice via short term (STM) and long-term memory (LTM) tests. (B) Latency of target in Barnes Maze acquisition period over the five days of training and in STM and LTM tests by female mice. (C-D) The behavior of male mice was examined at 12 months of age after mice were fed the indicated diets for 6 months. (C) The preference for a novel object over a familiar object was assayed in male mice via short term (STM) and long-term memory (LTM) tests. (D) Latency of target in Barnes Maze acquisition period over the five days of training and in STM and LTM tests by male mice. (A-D) n=6–10 biologically independent mice per group. (A, C, B and D (middle and right panels)) statistics for the overall effects of genotype (GT), diet, and the interaction represent the p value from a 2-way ANOVA, *p<0.05, from a Sidak’s post-test examining the effect of parameters identified as significant in the 2-way ANOVA. (B and D, left panel) *p<0.05, 3xTg vs. 3xTg-PR, Sidak’s test post 2-way RM ANOVA. Data represented as mean ± SEM.
Figure 9:
Figure 9:. PR promotes survival of 3xTg mice.
(A-B) Kaplan-Meier plots of the survival of female (A) and male (B) NTg and 3xTg mice fed the indicated diets starting at 6 months of age. n=8–10 (A), n=10–21 (B) biologically independent mice per group; p-value from log-rank test, 3xTg vs. 3xTg-PR. The two-tailed stratified log-rank p-value for the decrease in lifespan as a result of male sex and the increase in lifespan as a result of PR diet is shown. The overall effect of male sex (M) and PR diet (PR) was determined using a Cox proportional hazards test (HR, hazard ratio).

References

    1. Sibener L. et al. Alzheimer’s Disease prevalence, costs, and prevention for military personnel and veterans. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 10, S105–110, doi:10.1016/j.jalz.2014.04.011 (2014). - DOI - PubMed
    1. Duran-Aniotz C. & Hetz C. Glucose Metabolism: A Sweet Relief of Alzheimer’s Disease. Curr Biol 26, R806–809, doi:10.1016/j.cub.2016.07.060 (2016). - DOI - PubMed
    1. Schneider L. S., Insel P. S., Weiner M. W. & Alzheimer’s Disease Neuroimaging, I. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging Initiative. Archives of neurology 68, 58–66, doi:10.1001/archneurol.2010.343 (2011); - DOI - PMC - PubMed
    1. Shi M., Chu F., Zhu F. & Zhu J. Impact of Anti-amyloid-beta Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Front Aging Neurosci 14, 870517, doi:10.3389/fnagi.2022.870517 (2022); - DOI - PMC - PubMed
    1. Soderberg L. et al. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease. Neurotherapeutics 20, 195–206, doi:10.1007/s13311-022-01308-6 (2023); - DOI - PMC - PubMed

Publication types